Absci rises on Phase 1 ABS-201 update and $100 million raise
Absci shares soared 35% to $10.01 after early safety data showed its experimental hair-loss antibody ABS-201 was well tolerated in Phase 1, with no serious adverse events, and the company raised $100 million in a stock offering to fund further trials; interim proof-of-concept efficacy data are expected in the second half of 2026.